Demographic, clinical, and laboratory parameters of cystic fibrosis during the last two decades: a comparative analysis

BMC Pulmonary Medicine

Jose Dirceu Ribeiro¹  Katia Cristina Alberto Aguiar¹  Tais Daiene Russo Hortencio¹  Fernando Augusto de Lima Marson² 

[1] Departments of Pediatrics, State University of Campinas - Unicamp, Faculty of Medical Sciences, Campinas, Brazil;Departments of Medical Genetics, State University of Campinas - Unicamp, Faculty of Medical Sciences, Campinas, Brazil

关键词: Lung disease;    Epidemiology;    Cystic fibrosis;   

Others  :  1122252
DOI  :  10.1186/1471-2466-15-3

 received in 2013-08-06, accepted in 2015-01-06,  发布年份 2015

【 摘 要 】

Background

In recent years, patients with cystic fibrosis (CF) have tended to experience a longer life expectancy and higher quality of life. In this context, the aim of the present study was to evaluate and compare the demographic, clinical, and laboratory markers of patients with CF during the last two decades at a CF referral center.

Methods

A retrospective study of the demographic, clinical, and laboratory markers for CF treatment at a CF referral center was performed during two decades: 2000 (DI, 1990–2000, n = 104 patients) and 2010 (DII, 2000–2010, n = 181 patients).

Results

The following variables were less common in DI than in DII: (i) pancreatic insufficiency, (ii) meconium ileus, (iii) diabetes mellitus, (iv) Burkholderia cepacia colonization, (v) moderate and severe Shwachman-Kulczycki score (SKS), (vi) F508del mutation screening, (vii) patients without an identified CFTR mutation (class IV, V, or VI mutation), (viii) patients above the 10th percentile for weight and height, (ix) restrictive lung disease, and (x) older patients (p < 0.01). The following variables were more common in DI than in DII: (i) excellent and good SKS, (ii) F508del heterozygous status, (iii) colonization by mucoid and nonmucoid Pseudomonas aeruginosa, (iv) obstructive lung disease, and (v) minimal time for CF diagnosis (p < 0.01).

Conclusion

Clinical outcomes differed between the two decades. Demographic, clinical, and laboratory markers in patients with CF are useful tools and should be encouraged in CF referral centers to determine the results of CF management and treatment, enabling a better understanding of this disease and its clinical evolution. Early diagnosis and management of CF will improve patients’ quality of life and life expectancy until personalized drug therapy is possible for all patients with CF.

【 授权许可】

   
2015 Marson et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, Drumm ML, Iannuzzi MC, Collins FS, Tsui LC: Identification of the cystic fibrosis gene: cloning and characterization of the complementary DNA. Science 1989, 245:1066-1073.
• [2]Kerem BS, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC: Identification of the cystic fibrosis gene: genetic analysis. Science 1989, 245:1073-1080.
• [3]Rommens JM, Iannuzzi MC, Kerem BS, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N, Zsiga M, Buchwald M, Riordan JR, Tsui LC, Collins FS: Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989, 245:1059-1065.
• [4]Clinical and Functional Translation of CFTR. http://www.cftr2.org/ webcite
• [5]NCBI Gene: CFTR cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) [Homo sapiens (human)] [http://www.ncbi.nlm.nih.gov/gene/1080 webcite]
• [6]Cystic Fibrosis Mutation Database. http://www.genet.sickkids.on.ca/app webcite
• [7]Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd: Cystic Fibrosis Foundation: Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008, 153:S4-S14.
• [8]Rowe SM, Miller S, Sorscher EJ: Mechanisms of disease: cystic fibrosis. N Engl J Med 2005, 352:1992-2001.
• [9]Fanen P, Wohlhuter-Haddad A, Hinzpeter A: Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies. Int J Biochem Cell Biol 2014, 52:94-102.
• [10]Vallières E, Elborn JS: Cystic fibrosis gene mutations: evaluation and assessment of disease severity. Adv Genomics Genet 2014, 4:161-172.
• [11]McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, Ratjen F, Sermet-Gaudelus I, Plant B, Munck A, Jiang Y, Gilmartin G, Davies JC, VX08-770-105 (PERSIST) Study Group: Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2014, S2213–2600(14):902-910.
• [12]Agent P, Morison L, Prasad A: Standards for the clinical care of children and adults with cystic fibrosis in the UK – second edition. Cystic Fibrosis Trust 2011, 1-46.
• [13]Alvarez AE, Ribeiro AF, Hessel G, Bertuzzo CS, Ribeiro JD: Cystic fibrosis at a Brazilian center of excellence: clinical and laboratory characteristics of 104 patients and their association with genotype and disease severity. J Pediatr (Rio J) 2004, 80:371-379.
• [14]American Thoracic Society (ATS). http://www.thoracic.org/ webcite
• [15]Santos CIS, Ribeiro JD, Ribeiro AF, Hessel G: Critical analysis of scoring systems used in the assessment of Cystic Fibrosis severity: state of the art. J Bras Pneumol 2004, 30:286-298.
• [16]SPSS 21.0 for Windows (computer program). Statistical Package for Social Science (SPSS). Release Version 21.0 Chicago (IL): SPSS. Incorporation; 2013 [http://www.spss.com webcite]
• [17]Cystic Fibrosis Foundation http://www.cff.org webcite
• [18]Cystic Fibrosis Trust [http://www.cftrust.org.uk webcite]
• [19]Sims EJ, Green MW, Mehta A: Decreased lung function in female but not male subjects with established cystic fibrosis–related diabetes. Diabetes Care 2005, 28:1381-1387.
• [20]Anjorin A, Schmidt H, Posselt HG, Smaczny C, Ackermann H, Deimling M, Vogl TJ, Abolmaali N: Comparative evaluation of chest radiography, low-field MRI, the Shwachman-Kulczycki score and pulmonary function tests in patients with cystic fibrosis. Eur Radiol 2008, 18:1153-1161.
• [21]Davies JC, Alton EW: Monitoring respiratory disease severity in cystic fibrosis. Respir Care 2009, 54:606-617.
• [22]Mishra A, Greaves R, Smith K, Carlin JB, Wootton A, Stirling R, Massie J: Diagnosis of cystic fibrosis by sweat testing: age-specific reference intervals. J Pediatr 2008, 153:758-763.
• [23]Drumm ML, Ziady AG, Davis PB: Genetic variation and clinical heterogeneity in cystic fibrosis. Annu Rev Pathol 2012, 7:267-282.
• [24]Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL, EPIC Study Group Participating Clinical Sites: Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the Cystic Fibrosis EPIC Observational Cohort. Pediatr Pulmonol 2010, 45:934-944.
• [25]Wagener JS, Zemanick ET, Sontag MK: Newborn screening for cystic fibrosis. Curr Opin Pediatr 2012, 24:329-335.
• [26]Yen EH, Quinton H, Borowitz D: Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr 2013, 162:530-535.
• [27]Scaparrotta A, Di Pillo S, Attanasi M, Consilvio NP, Cingolani A, Rapino D, Mohn A, Chiarelli F: Growth failure in children with cystic fibrosis. J Pediatr Endocrinol Metab 2012, 25:393-405.
• [28]Blackman SM, Hsu S, Vanscoy LL, Collaco JM, Ritter SE, Naughton K, Cutting GR: Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J Clin Endocrinol Metab 2009, 94:1302-1309.
• [29]Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W: Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 2009, 32:1626-1631.
• [30]Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI: Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010, 33:311-316.
• [31]Laguna TA, Nathan BM, Moran A: Managing diabetes in cystic fibrosis. Diabetes Obes Metab 2010, 12:858-864.
• [32]Australia CF: Cystic Fibrosis in Australia 2009: 12th Annual Report from the Australian Cystic Fibrosis Data Registry. Sydney: Cystic Fibrosis Australia; 2011.
• [33]Gorter RR, Karimi A, Sleeboom C, Kneepkens CMF, Heij HA: Clinical and genetic characteristics of meconium ileus in newborns with and without cystic fibrosis. J Pediatr Gastroenterol Nutr 2010, 50:569-572.
• [34]Paraskeva MA, Borg BM, Naughton MT: Spirometry. Aust Fam Physician 2011, 40:216-219.
• [35]Gibson LE, Cooke RE: A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959, 23:545-549.
• [36]Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, Cavalcoli JD, VanDevanter DR, Murray S, Li JZ, Young VB, LiPuma JJ: Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci 2012, 109:5809-5814.
• [37]Quinton P, Molyneux L, Ip W, Dupuis A, Avolio J, Tullis E, Conrad D, Shamsuddin AK, Durie P, Gonska T: β-adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Am J Respir Crit Care Med 2012, 186:732-739.
• [38]Sousa M, Servidoni MF, Vinagre AM, Ramalho AS, Bonadia LC, Felício V, Ribeiro MA, Uliyakina I, Marson FA, Kmit A, Cardoso SR, Ribeiro JD, Bertuzzo CS, Sousa L, Kunzelmann K, Ribeiro AF, Amaral MD: Measurements of CFTR-mediated Cl- secretion in human rectal biopsies constitute a robust biomarker for cystic fibrosis diagnostic and prognosis. PLoS One 2012, 7:e47708.
• [39]Guss AM, Roeselers G, Newton IL, Young CR, Klepac-Ceraj V, Lory S, Cavanaugh CM: Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J 2011, 5:20-29.
• [40]Park JE, Yung R, Stefanowicz D, Shumansky K, Akhabir L, Durie PR, Corey M, Zielenski J, Dorfman R, Daley D, Sandford AJ: Cystic fibrosis modifier genes related to Pseudomonas aeruginosa infection. Genes Immun 2011, 12:370-377.
• [41]Marson FA, Bertuzzo CS, Ribeiro AF, Ribeiro JD: Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis. BMC Pulm Med 2012, 12:50. BioMed Central Full Text
• [42]Marson FAL, Bertuzzo CS, Ribeiro MÂ, Ribeiro AF, Ribeiro JD: Screening for F508del as a first step in the molecular diagnosis of cystic fibrosis. J Bras Pneumol 2013, 39:306-316.
• [43]Bonadia LC, Marson FAL, Ribeiro JD, Paschoal IA, Pereira MC, Ribeiro AF, Bertuzzo CS: CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease. Gene 2014, 540:183-190.
• [44]Bieger AM, Marson FA, Bertuzzo CS: Prevalence of ΔF508 mutation in the cystic fibrosis transmembrane conductance regulator gene among cystic fibrosis patients from a Brazilian referral center. J Pediatr 2012, 88:531-534.
• [45]Tuchman LK, Schwartz LA, Sawicki GS, Britto MT: Cystic fibrosis and transition to adult medical care. Pediatrics 2010, 25:566-573.